Drug Development

Listings
  • Anti-CEACAM5 (clone huMAb2-1)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-1)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-1) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-3)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-3)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-3)-sulfoSPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-3)-sulfoSPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a sulfoSPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocy...

  • Anti-CEACAM5 (clone huMAb2-4)-SPDB-DM4 ADC

    Anti-CEACAM5 (clone huMAb2-4)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-4) conjugated via a SPDB linker to a DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (clone huMAb2-3)-SMCC-DM1 ADC

    Anti-CEACAM5 (clone huMAb2-3)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a SMCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis...

  • Anti-CEACAM5 (Labetuzumab)-CL2A-SN-38 ADC

    Anti-CEACAM5 (Labetuzumab)-CL2A-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a CL2A linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 i...

  • Anti-CEACAM5 (Labetuzumab)-CL1-SN-38 ADC

    Anti-CEACAM5 (Labetuzumab)-CL1-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a CL1 linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is...

  • Anti-CEACAM5 (Labetuzumab)-CL3-SN-38 ADC

    Anti-CEACAM5 (Labetuzumab)-CL3-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a CL3 linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is...

  • Anti-CEACAM5-Phy-lys-SN-38 ADC

    Anti-CEACAM5-Phy-lys-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a Phy-lys linker to SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the...

  • Anti-CEACAM6 (hMN15)-CL2A-SN-38 ADC

    Anti-CEACAM6 (hMN15)-CL2A-SN-38 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CEACAM6 monoclonal antibody (hMN15) conjugated via a CL2A linker to SN-38 . The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. With...

  • Anti-cKIT (9P3)-SMCC-DM1 ADC

    Anti-cKIT (9P3)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (9P3) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Anti-cKIT (NEG085)-SMCC-DM1 ADC

    Anti-cKIT (NEG085)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (NEG085) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...